- Home
- NYXH vs TLSA Comparison
NYXH vs TLSA Comparison
Compare NYXH & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYXH | TLSA |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Belgium | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8M | 155.2M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NYXH | TLSA |
|---|---|---|
| Price | $3.31 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.25 | N/A |
| AVG Volume (30 Days) | 55.8K | ★ 144.3K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $214.32 | N/A |
| Revenue Next Year | $124.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.73 |
| 52 Week High | $8.64 | $2.60 |
Technical Indicators
Market Signals| Indicator | NYXH | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 46.80 |
| Support Level | $2.76 | $1.26 |
| Resistance Level | $3.32 | $1.62 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 59.66 | 36.84 |
Price Performance
Historical ComparisonAbout NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.